U.S., Oct. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07220811) titled 'Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy' on Oct. 22.
Brief Summary: Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In...